Actuate Therapeutics, Inc. (ACTU) Income Statement
ACTU 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsACTU revenue and net income
ACTU growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ACTU quarterly EPS vs estimates
Actuate Therapeutics beat the analyst EPS estimate in 4 of the last 7 quarters. Next report: November 12, 2026 (estimate $-0.18).
ACTU income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research & development | $10.3M | $18.7M | $21.7M | $16.4M |
| Sales, general & admin | $12.2M | $6.5M | $3.3M | $3.8M |
| Total operating expenses | $22.5M | $25.2M | $25.0M | $20.2M |
| Operating income | −$22.5M | −$25.2M | −$25.0M | −$20.2M |
| Interest income | $287,710 | $222,293 | $352,672 | $27,027 |
| Interest expense | $20,250 | $18,717 | $43,641 | $16,200 |
| Income before taxes | −$22.2M | −$27.3M | −$24.7M | −$20.2M |
| Income taxes | $800 | $800 | — | — |
| Net income | −$22.2M | −$27.3M | −$24.7M | −$20.2M |
| EBITDA | −$22.2M | −$2.1M | $272,849 | $63,606 |
| EPS (diluted) | −$1.05 | −$5.08 | −$1.62 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $2.1M | $2.6M | $2.1M | $2.2M | $2.8M | $3.2M | $3.7M | $3.8M | $4.4M | $6.9M | $6.6M | $5.8M |
| Sales, general & admin | $2.8M | $3.1M | $2.6M | $3.3M | $3.2M | $3.1M | $2.9M | $1.6M | $1.1M | $912,824 | $969,354 | $714,167 |
| Total operating expenses | $4.9M | $5.7M | $4.7M | $5.5M | $6.0M | $6.4M | $6.6M | $5.4M | $5.4M | $7.8M | $7.6M | $6.5M |
| Operating income | −$4.9M | −$5.7M | −$4.7M | −$5.5M | −$6.0M | −$6.4M | −$6.6M | −$5.4M | −$5.4M | −$7.8M | −$7.6M | −$6.5M |
| Interest income | $45,016 | $85,269 | $139,582 | $69,971 | $24,534 | $53,623 | $118,115 | $80,747 | $8,645 | $14,786 | $59,688 | $125,944 |
| Interest expense | $5,063 | $5,062 | $5,062 | $5,063 | $5,062 | $5,063 | $5,076 | $3,489 | $5,076 | $5,076 | $5,063 | $5,062 |
| Income before taxes | −$4.9M | −$5.6M | −$4.6M | −$5.4M | −$5.9M | −$6.3M | −$6.4M | −$6.0M | −$6.6M | −$8.3M | −$7.6M | −$6.3M |
| Income taxes | — | — | $800 | — | — | — | — | — | — | — | — | — |
| Net income | −$4.9M | −$5.6M | −$4.6M | −$5.4M | −$5.9M | −$6.3M | −$6.4M | −$6.0M | −$6.6M | −$8.3M | −$7.6M | −$6.3M |
| EBITDA | −$4.9M | −$5.6M | −$4.5M | −$5.4M | −$5.9M | −$6.3M | −$6.3M | −$6.0M | −$6.6M | −$8.3M | −$7.6M | −$6.2M |
| EPS (diluted) | −$0.20 | −$0.24 | −$0.18 | −$0.25 | −$0.30 | −$0.32 | −$0.33 | −$0.55 | −$4.20 | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ACTU's financial statements (latest annual report filed March 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ACTU financial results
Actuate Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $22.2 million. Diluted earnings per share came to −$1.05.
See the ACTU stock overview for the latest quote and news, or the ACTU chart for price history and technical indicators.
ACTU income statement FAQ
Does Actuate Therapeutics have revenue?
Actuate Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Actuate Therapeutics profitable?
No. Actuate Therapeutics reported a net loss of $22.2 million in fiscal 2025.
How much does Actuate Therapeutics spend on research and development?
Actuate Therapeutics spent $10.3 million on research and development in fiscal 2025.
What are Actuate Therapeutics's earnings per share?
Actuate Therapeutics earned $-1.05 per diluted share in fiscal 2025, compared with $-5.08 a year earlier.
When will Actuate Therapeutics report its next earnings?
Actuate Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes.
When does Actuate Therapeutics's fiscal year end?
Actuate Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 26, 2026.